
Michael McShea, RPH
Advertisement
Articles by Michael McShea, RPH


Pharmacists must be experts on follow-on biologics (FOBs), including biosimilars, so they can provide education to health professionals about safe prescribing and use, which ultimately affects patient care.

Pharmacists need to be experts on follow-on biologics, including biosimilars, so they can provide education to health professionals about safe prescribing and use.

Health care practitioners need to prepare for myriad questions regarding biosimilars and follow-on biologic drugs as they enter the market.
Advertisement
Latest Updated Articles
Biosimilars and Follow-on Biologics: A Pharmacist OpportunityNovember 16th 2016
Biosimilars and Follow-on BiologicsSeptember 28th 2017
Biosimilars and Follow-on Biologics: A Pharmacist OpportunityOctober 12th 2016
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
FDA Grants Accelerated Approval to Ravulizumab for Proteinuria Reduction in IgA Nephropathy
4
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
5

